UVM Center on Disability & Community Inclusion (CDCI) Project SCOPE: two parents hold a tow-headed blonde child in a pink tshirt by the hands between them.

The goal of Project SCOPE Vermont is to help providers develop effective screening, monitoring, and interdisciplinary support for children and families with Neonatal Abstinence Syndrome. 

Neonatal Abstinence Syndrome, or NAS, is a medical condition in infants who go into opioid withdrawal shortly after they're born.

Learning Sessions and Registration

Learn more about Project SCOPE VT

 

 

Why Project SCOPE Vermont?

The CDCI is receiving support from the Wyoming Institute for Disabilities (WIND) to improve training & supports for children and families with Neonatal Abstinence Syndrome (NAS). The work is called Project SCOPE: Supporting Children of the OPioid Epidemic.

Vermont has one of the highest rates of NAS in the U.S. And for 20 years, Vermont has worked to decrease barriers for pregnant people to receive addiction treatment. A key initiative working on this is Project ICON (Improving Care for Opioid-Exposed Newborns) at the UVM Larner College of Medicine.

Funding: This project is supported in part by grant number 90DDUC0062, from the U.S. Administration for Community Living, Department of Health and Human Services, Washington, D.C. 20201.​​ Grantees undertaking projects with government sponsorship are encouraged to express freely their findings and conclusions. Points of view or opinions do not, therefore, necessarily represent official ACL policy.​

Project SCOPE logo: a cartoon showing a woman sitting in a chair on one side of the image, holding out a book. On the other side of the image a small child sits on the floor, arms raised happily. In the middle, the Project SCOPE logo: a child inside a heart.

Question mark in a circleIf you'd like the materials on this website in a different format, or have questions relating to how the materials in the ECHO trainings will be presented, or any other questions about accessibility, please email Audrey Homan.